Deerfield/ Dana-Farber’s USD 130 Million Cancer Research Deal; FDA-Approval to BMS’ Breyanzi & TG Therapeutics’ Ukoniq; EU Marketing Rights for ViiV Healthcare’s Rukobia
Delveinsight
FEBRUARY 9, 2021
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s (BMS) CAR T-cell therapy Breyanzi , for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including Diffuse large B-cell lymphoma (DLBCL).
52 
Let's personalize your content